Zenas BioPharma, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Zenas BioPharma amended and restated its 2024 Employee Stock Purchase Plan effective May 18, 2026. The plan authorizes 397,956 shares initially, with automatic annual increases of 1% of outstanding shares (capped at 1M shares/year) through 2034. Employees may contribute 1–15% of eligible compensation via payroll deduction to purchase stock at 85% of fair market value, measured as the lower of grant-date or exercise-date FMV. The plan includes 423 and non-423 components for tax compliance.
Why this rating
Routine equity plan amendment. Share pool (397K–1M annually) is <0.5% of company market cap (~$259M). Standard ESPP terms; no material change to capital structure or shareholder value.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.